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Abstract
Background: Recent evidence suggests that several human cancers are capable of uncoupling of
mitochondrial ATP generation in the presence of intact tricarboxylic acid (TCA) enzymes. The goal
of the current study was to test the hypothesis that ketone bodies can inhibit cell growth in
aggressive cancers and that expression of uncoupling protein 2 is a contributing factor. The
proposed mechanism involves inhibition of glycolytic ATP production via a Randle-like cycle while
increased uncoupling renders cancers unable to produce compensatory ATP from respiration.
Methods: Seven aggressive human cancer cell lines, and three control fibroblast lines were grown
in vitro in either 10 mM glucose medium (GM), or in glucose plus 10 mM acetoacetate [G+AcA].
The cells were assayed for cell growth, ATP production and expression of UCP2.
Results: There was a high correlation of cell growth with ATP concentration (r = 0.948) in a
continuum across all cell lines. Controls demonstrated normal cell growth and ATP with the lowest
density of mitochondrial UCP2 staining while all cancer lines demonstrated proportionally inhibited
growth and ATP, and over-expression of UCP2 (p < 0.05).
Conclusion: Seven human cancer cell lines grown in glucose plus acetoacetate medium showed
tightly coupled reduction of growth and ATP concentration. The findings were not observed in
control fibroblasts. The observed over-expression of UCP2 in cancer lines, but not in controls,
provides a plausible molecular mechanism by which acetoacetate spares normal cells but
suppresses growth in cancer lines. The results bear on the hypothesized potential for ketogenic
diets as therapeutic strategies.
Background
Otto Warburg observed that many cancers lose their
capacity for mitochondrial respiration, limiting ATP pro-
duction to anaerobic glycolytic pathways [1]. The phe-
nomenon is particularly prevalent in aggressive
malignancies, most of which are also hypoxic. Hypoxia
induces a stochastic imbalance between the number of
reduced mitochondrial species vs. available oxygen, result-
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ing in increased reactive oxygen species (ROS) whose tox-
icity can lead to apoptotic cell death. One mitochondrial
adaptation to increased ROS is over-expression of uncou-
pling protein 2 (UCP2) which has been reported in a
number of human cancer cell lines [2-4]. Horimoto et al.
[3] demonstrated UCP2 over-expression in most of the
120 colon cancer lines tested, the extent correlating with
the degree of tumor aggressiveness. Increased UCP2
expression was also associated with reduction in ATP pro-
duction in malignant oxyphilic thyroid tumors [2], and in
mouse leukemia and human lymphoma cell lines [4]. It is
reasonable to ask whether one can take advantage of the
ability of UCP2 to disrupt regulation of ATP generation in
cancer as a therapeutic method.
One mechanism by which aggressive cancers that over-
express UCP2 might inhibit glycolytic ATP is the so-called
Randle cycle. In normal cells, the Randle cycle has been
proposed as a mechanism by which increased availability
of fatty acids and ketone bodies from lipolysis inhibit gly-
colysis in order to maintain stable production of ATP.
Products of lipolysis, according to this mechanism, supply
acetyl-CoA for the TCA cycle whose intermediates inhibit
glycolysis [5]. We propose that aggressive cancers, under
conditions of ketosis, employ a Randle-like cycle to
inhibit glycolytic ATP generation, but, in contrast to nor-
mal cells, cannot supply compensatory mitochondrial
ATP due to uncoupling.
We have cultured three human primary fibroblast lines
and seven human cancer cell lines in media of varying glu-
cose and ketone body content to compare cell growth
rates, ATP concentration, and expression of UCP2. Restric-
tion of cancer cell lines to colon and breast was meant to
parallel the kinds of patients we expect to be eligible for
our ongoing clinical trial of very low carbohydrate diets in
advanced cancer[6]. (The trial is registered with Clinical-
Trials.gov; Registry No. NCT00444054; with information
available at http://clinicaltrials.gov/ct2/show/
NCT00444054).
Materials and methods
Cell lines
Human cell lines representing colon cancers (Lovo, RKO,
CaCO2, SW48, SW480) and breast cancers (MDA MB
231, MCF7) were purchased from ATCC, and control lines
of normal human fibroblasts RFP3, MCH 064 and MCH
065 were obtained from other sources. Cells were cultured
in DMEM with 10% fetal calf serum and 10 mM glucose
in 4% CO2 at 37°C. Cells were plated into twelve well
plates at a density of 105 per ml into their respective media
and were maintained for 24, 48, 72, and 96 h to deter-
mine their growth curves. For cells maintained in culture
of 72 and 96 h, medium was replaced at 48 h. Cells were
harvested by trypsinization and cell count and viability
were determined in the presence of trypan blue dye using
a hemocytometer. Glucose concentrations were varied
from 5 mM, 10 mM, 25 mM, 50 mM and 100 mM to
determine optimum growth conditions. All plated cell
lines were incubated in duplicate or triplicate.
Materials
Modified DMEM without glucose, glutamine, and pyru-
vate, 100× NEAA and Lithium acetoacetate (Sigma), fetal
bovine serum (GIBCO) 100× glutamine, 100× pyruvate,
Trypsin: EDTA solution, normal goat serum, 100× antibi-
otic solution and ATP determination kit (Gibco/Invitro-
gen); rabbit anti-UCP2 (human-Biolegend); goat anti-
rabbit IgG (H+L)-HRP conjugate (Vector Labs).
Assays
Cellular ATP and protein content
ATP content in the cells was assayed using a luciferase
assay kit (Sigma). Total protein was assayed using the Bio-
rad protein assay kit and the ATP content was expressed
per cell, and per mg of cellular protein.
Immunohistochemistry
Cells grown in 12 well plates for 96 h were dissociated
with 0.5 ml Trypsin:EDTA solution, re-suspended in equal
volume of DMEM containing 10% FBS, washed twice in
one ml PBS, followed by centrifugation at 2800 rpm for 3
min. Cells were re-suspended in 4 volumes of PBS, spread
on aminosilane coated slides and air dried overnight.
Doubly PBS-washed slides were blocked with 10% nor-
mal goat serum in PBS for 30 min. at room temperature.
The slides were then incubated in rabbit anti-UCP2
(human) Ab diluted 1:200 in 10% normal goat serum-
PBS for 2 h at room temperature or overnight 4°C. Slides
washed in PBS were incubated in 1:2000 dilutions of goat
anti-rabbit IgG (H+L)-HRP conjugated secondary Ab in
10% normal goat serum -PBS for 1 h at room temperature
then washed in PBS again. Slides were then incubated in
DAB peroxidase substrate for 6–10 minutes, washed in
water, dehydrated through alcohols and xylenes and cov-
ered with permount medium and glass cover slip.
Quantitation of UCP2 immunostaining using ImageJ
All cell types placed on a slide were simultaneously immu-
nostained for UCP2 as previously described and photo-
graphed at 100× magnification using a Nikon Labophot-
2 microscope equipped with a Nikon D70 digital camera.
The relative intensity of UCP staining per cell was deter-
mined using ImageJ  version 1.39 (NIH, USA: for latest
supported version see http://rsbweb.nih.gov/ij/down
load.html).
Briefly, RGB composite images containing both control
cells (normal human fibroblasts) and various cancer cell
lines were created using Photoshop CS. The compositeCancer Cell International 2009, 9:14 http://www.cancerci.com/content/9/1/14
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files were opened within ImageJ and converted to 32 bit
grayscale images. Following this conversion the threshold
for analysis was automatically chosen for the entire com-
posite image by ImageJ. A frame was then drawn around
each cell type in the composite image and a particle anal-
ysis was performed that generated data containing both
the cell count and the intensity of stain per cell. The frame
was then moved to another cell type within the composite
image and the analysis re-performed.
All UCP2 results were reported using the immunostain
method with ImageJ analysis of optical density.
Specificity of immunostain and quantitation of UCP2 with ELISA 
sandwich assay
An ELISA sandwich assay was developed that was directed
against widely separated peptide fragments of UCP2.
Details of preparation will be published elsewhere. In
brief, UCP2 antigen and rabbit anti-human UCP2 as pri-
mary antibody (recombinant N-terminal partial frag-
ment) were obtained from Biolegend. A secondary
antibody for the sandwich assay was Goat anti-rabbit HRP
H&L from Vector Labs. TMB was reacted with the peroxi-
dase and absorbance was measured at 450 nm. Results of
UCP2 by ELISA were correlated with ImageJ analysis for
RFP3, SW48, and MDA MB 231 to assess specificity of the
immunostain method.
Statistics
Correlation of ATP/mg protein with cell growth was per-
formed using linear least squares regression fit. UCP2 OD
and ATP/mg protein were compared among all cell lines
using two-way ANOVA. Correlations at p < 0.05 level were
considered significant. Comparisons of UCP2 in cancer
lines vs. mean fibroblast values were performed by the
Student t-test with Bonferroni correction.
Results
Preliminary examination of cell culture of all lines dem-
onstrated a peak in cell growth rates at either 10 mM glu-
cose or 25 mM glucose compared with higher or lower
concentrations. 50 mM and 100 mM glucose suppressed
cell growth, likely from hypertonicity. Ninety-six h per-
mitted maximum growth before plate saturation and was
selected as the optimal time for cell counting. It was found
that 10 mM glucose medium (GM) was as effective at pro-
moting growth as 25 mM and, because it is closer to phys-
iologic human concentrations, was chosen for further
experimental testing.
In order to compare the effect of acetoacetate (AcA) on
growth, cell counts at 96 h in the combined glucose plus
acetoacetate medium (G+AcA) were compared to 96 h G
alone which was defined as 100%. Table 1 shows values
for cell growth by this definition and in absolute cell num-
bers. Values are also shown for ATP/mg cell and UCP2 as
optical densities from scanned photographs of cells
stained with peroxidase.
Specificity of assays
The UCP2 ELISA sandwich assay demonstrated a linear
relationship for the standard curve of UCP2 antigen (Bio-
legend) vs. ELISA (r = 0.988) (Figure 1A). Lysates of RFP3,
SW48 and MDA MB 231 were also assayed at varying con-
centrations up to 1000 fold excess total protein. The cal-
culated UCP2 value from the standard curve remained
highly linear (Figures 1B, C, and 1D) without evidence of
non-specific binding. The UCP2 values in cell lines tested
by ELISA remain in the same relation as the immunostain
method. ImageJ-derived OD (y) correlates with the
ELISA(x) [y = 122.7x + 13.5; r = 0.93, p < 0.01; data not
shown]. There was no correlation between the expression
of cellular protein and the % change in ATP due to acetoa-
cetate (Figure 2).
Effects on cell growth and ATP concentration
Control fibroblasts from a normal adult (RFP3) and from
neonates (MH 064 and 065) showed no reduction in
either cell growth or ATP concentration in G+AcA
medium, whereas all cancer lines showed parallel reduc-
tions in ATP and growth when cultured in G+AcA (Table
1 and Figure 3A). ATP reduction and cell growth inhibi-
tion show a linear correlation by least squares regression,
g = 1.03a +6.5; r = 0.95 (p < 0.001) (Figure 3B).
UCP2 expression displayed variation at 96 h depending
on the growth medium (GM vs. G + AcA), but all cancer
lines showed higher values in either medium compared
with fibroblasts (p < 0.05) (Figure 4). Peroxidase staining
of MDA MB231 is contrasted with RFP3 in Figure 5. There
was an inverse linear relation between ATP concentration
and UCP2 expression in acetoacetate medium (Figure 6; r
= 0.66, p < 0.05).
Discussion
The uncoupling proteins (UCP's) constitute a structurally
related family with variable ability to uncouple mitochon-
drial production of ATP [7][8,9]. Uncoupling reduces the
proton gradient across the inner mitochondrial mem-
brane. UCP1, first discovered in rodents, is present in
brown fat in infants but its abundance decreases strikingly
in most people with age, along with the reduction of
brown fat tissue. UCP2 has about 58% structural homol-
ogy with UCP1. While UCP2 concentration is very low or
absent in most normal tissues it has been found to be
more highly expressed in aging vs. young fibroblasts [10],
in pancreatic islets in type 2 diabetes mellitus[11], and in
macrophages under inflammatory stimulation [7,12]. In
all these cases its presence has been postulated to repre-
sent an adaptive reaction to increased reactive oxygen spe-Cancer Cell International 2009, 9:14 http://www.cancerci.com/content/9/1/14
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Table 1: 96 h cell lines grown in 10 mM glucose either with or without acetoacetate*
Cell line
[Acetoacetate]d ATPe nmols/mg 
protein
%ATPf Cell count ×106/ml %cell countg UCP2 OD % viability Total Protein/106 
cells
% total Protein
RFP3
*0 85.2 100% 0.85 100% 66.0 99.7 9.85 100%
*10 mM 90.2 106% 0.805 94.7% 47.7 99.7 10.63 107.9%
MCH 064
*0 146.3 100% 0.126 100% 104.5 94.0 7.61 100%
*10 mM 185.8 127% 0.140 111.1% 69.7 98.2 8.80 115.6%
MCH 065
*0 198.5 100% 0.198 100% 80.0h 98.8 8.75 100%
*10 mM 184.5 93.2% 0.206 101.5% 59.9h 97.0 9.45 108.0%
SW48
*0 693.5 100% 1.94 100% 177.7 99.4 7.8 100%
*10 mM 303.5 43.8% 0.76 39% 109.7 100 7.7 98.7%
SW480
*0 597.0 100% 1.39 100% 182.7 95.5 12.8 100%
*10 mM 428.5 71.8% 0.79 57% 161.8 93.5 11.6 90.6%
RKO
*0 700.0 100% 5.40 100% 221.1 100 14.6 100%
*10 mM 371.0 53% 2.74 50.7 181.5 100 12.6 86.3%
MCF-7Cancer Cell International 2009, 9:14 http://www.cancerci.com/content/9/1/14
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cies (ROS). Controversy exists whether UCP2 causes
significant mitochondrial uncoupling or ROS inhibition
[13,14]. It is instructive, however, to note that tissues with
the highest UCP2 expression, as above, represent those
which generate high ROS; and that ROS mitigation could
be explained by mitochondrial uncoupling, an effect
observed only at high UCP2 concentrations. Cancers are
among the tissues reported to express UCP2 in much
higher concentrations than normal tissues [2-4]. Our pro-
posal starts with the assumption that UCP2 over-expres-
sion is an adaptive response which limits ROS in cancer
lines by causing uncoupling. The proposal asks whether
this assumption is borne out with consistent results under
specific experimental conditions.
An increase in UCP2 has been reported to be associated
with reduction of respiratory ATP production in several
cancer lines [2,4] that have preserved TCA cycle enzymes.
Horimoto et al [3] showed that UCP2 over-expression is
present in most  colon cancer lines, the degree of over-
expression correlating with the histologic grade. It was
proposed that UCP2 over-expression was an adaptive
mechanism that reduced ROS-induced apoptosis among
the cancer cells.
We suggest that ketone bodies, if metabolized in cancers
of this type, can inhibit glycoloysis and resultant ATP gen-
eration without compensatory mitochondrial respiratory
ATP production, thereby inhibiting cell growth.
*0 590.0 100% 0.87 100% 177.1 97.0 11.95 100%
*10 mM 540.5 91.6% 0.65 74.7% 148.2 91.5 10.8 90.5%
LOVO
*0 433.0 100% 1.02 100% 150.5 98.9 13.1 100%
*10 mM 293.5 67.8% 0.60 58.7% 205.2 97.9 9.50 68.3%
CaCO2
*0 296.5 100% 0.275 100% 224.7 93.5 7.10 100%
*10 mM 137.0 46.2% 0.140 50.9% 295.0 92.9 7.90 111.3%
MDA MB 231
*0 267.0 100% 0.72 100% 556.7 99.1 17.95 100%
*10 mM 161.5 60.5% 0.34 47.6% 341.5 99.3 21.0 117.0%
*For standard errors of all measurements see Figures 2 – 5 (based upon ATP and cell count studies performed in triplicate; and UCP2 
measurements performed in duplicate).
ATP and cell growth values in bold print are significantly lower (p < 0.05) than the values in glucose only medium for the same cell line. UCP2 
values in bold italics are significantly higher (p < 0.05) than mean of control fibroblast lines for each growth medium.
d [Acetoacetate] = Concentration of Acetoacetate in medium
e ATP production expressed as nmol ATP/mg protein
f % of ATP production at 96 h compared with 10 mM glucose and 0 mM acetoacetate (defined as 100%)
g Cell count expressed as % of 96 h growth in 10 mM glucose and 0 mM acetoacetate
h Calculated from the slope of its ELISA curve (0.043/μg protein, not shown) in comparison to Fig. 1B for RFP3 cells, then recalibrated to ImageJ 
OD/cell.
Table 1: 96 h cell lines grown in 10 mM glucose either with or without acetoacetate* (Continued)Cancer Cell International 2009, 9:14 http://www.cancerci.com/content/9/1/14
Page 6 of 11
(page number not for citation purposes)
The Randle cycle was proposed more than 30 years ago as
a mechanism whereby products of lipolysis (fatty acids
and ketone bodies) would inhibit glycolysis in normal
cells to maintain stable ATP production [5]. According to
this mechanism, abundant acetyl CoA causes feedback
inhibition of pyruvate dehydrogenase and increases the
level of TCA intermediates, specifically citrate, to inhibit
phosphofructokinase, both processes reducing the rate of
glycolysis. The relevance to normal metabolism has been
challenged by Wolfe et al [15,16]. These investigators
showed convincingly that under most physiologic condi-
tions carbohydrate-stimulated insulin secretion increases
intracellular glucose availability. Increased intracellular
glucose concentrations drive glycolysis, so that carbohy-
drate, via the dominating effect of insulin, becomes the
regulator of lipid metabolism rather the other way
around. Wolfe et al. pointed out that the Randle cycle has
only been persuasively demonstrated in in vitro prepara-
tions under conditions of euglycemic, hyperinsulinemic
clamp, in which intracellular glucose availability remains
high and fixed. Under these circumstances, in rat myocar-
dium preparations, for example, variable fatty acid availa-
bility does indeed regulate the rate of glycolysis.
Interestingly, high fixed intracellular glucose availability
is a likely condition in vivo for most aggressive cancer cells
whose membranes express high affinity insulin-independ-
ent  glucose 1 transporters (GLUT1) [17]. The Km for
GLUT1, at 18 mg/dl, predicts maximum fixed glucose
transport at ordinary physiologic glucose concentrations
Specificity of UCP2 ELISA Figure 1
Specificity of UCP2 ELISA. (A) Standard curve of UCP2 antigen is calibrated against sandwich ELISA assay (see text). (B) 
UCP2 is calculated from standard curve in cell lysates from RFP3, SW48 and MDA MB 231 (B, C, and D respectively). Slopes 
of regressions represent ng UCP2 per μg total protein.
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of 60–100 mg/dl. This contrasts with normal human tis-
sues (e.g. myocytes, adipocytes, endothelial cells) which,
capable of metabolizing lipids and carbohydrates, express
insulin-dependent GLUT4. Our hypothesis suggests that
metabolism of ketone bodies in cells over-expressing
GLUT1 and UCP2 may provide the opportunity for acetyl
COA and citrate to inhibit glycolysis, just as in the euglyc-
emic-hyperinsulinemic Randle cycle. However, UCP2
over-expression differs from the Randle model in that
uncoupling prevents full mitochondrial compensation of
ATP production. We consider this an "inefficient" Randle
cycle.
Evidence for such an inefficient Randle cycle is found in
the seven cancer lines of our investigation which demon-
strated parallel reductions in ATP concentration and cell
growth, the greatest inhibition found in CaCO2 and
SW48 lines, and the least in MCF7 (Figure 3B). In addi-
tion, UCP2 staining correlates inversely with ATP produc-
tion in all cells lines (Figure 4, 5). The three control
fibroblast cell lines demonstrated neither growth inhibi-
tion nor reduced ATP production, and showed the least
quantitative staining for UCP2 among all cell lines meas-
ured. The findings extend the observations of previous
investigators and point to a specific kind of mitochondrial
abnormality, UCP2 over-expression that under condi-
tions of ketosis is capable of reducing the growth rate of
certain cancers. We believe that the findings are also capa-
ble of reconciling apparently contradictory results in pre-
vious animal models. Tisdale et al. reported MAC16
tumor growth inhibition in mice on ketogenic diets [18]
but failure of ketosis to inhibit Walker carcinosarcoma
[19]. The latter tumor lacks the succinyl-CoA ketotrans-
ferase required to metabolize ketone bodies. Metabolism
of ketone bodies is required by the present hypothesis to
enable inhibition of glycolysis via the TCA cycle, and
therefore absence of this enzyme would predictably fail to
inhibit cancer growth.
There are limitations in the present study. The investiga-
tion does not prove metabolic inhibition of cancer growth
and ATP production due to uncoupling. Proof requires
direct demonstrations of acetoacetate metabolism as well
as inhibition of the rate of ATP production, not just of
steady state ATP concentrations. Second, glucose and ace-
toacetate were both incubated at supraphysiologic con-
centrations to maximize detectable effects. It is not
possible without further in vivo study to predict effects
under physiologic conditions. Third, in vitro culture of pri-
mary cell lines is difficult for normal human cell types,
and only fibroblasts were used as controls, so the response
of other normal tissue types was not measured. Further,
fibroblast lines capable of growth in cell culture are not
normal; however, neither are they the equivalent to malig-
nant cell lines and their difference from malignant lines
was demonstrated in this investigation. Also, the range of
tumor susceptibility to acetoacetate varies widely, plausi-
bly due to increased levels of UCP2 expression, but other
factors must be considered. For example SW48, with the
greatest reduction of ATP and cell growth in acetoacetate
medium, was a prominent outlier with the least UCP2
expression among the cancer cell lines (Figure 5). Finally,
we did not manipulate UCP2 expression using knock-
down and knock-in techniques. Single protein manipula-
tions, while very important, cannot be expected to reliably
predict phenotypic changes in light of growing awareness
of complex feedback regulation of gene-protein networks.
We plan to explore these manipulations in subsequent
investigation, until now having focused on phenotypic
behaviors of seven different cancer lines in contrast to
controls.
Cancers are notorious for their ability to evade metabolic
regulation [20] and therapeutic use of metabolic inhibi-
tors has been avoided until recently. Specifically targeted
pharmacologic inhibitors such as dichloroacetate [21]
and 2-deoxyglucose [22,23], the latter originally proposed
as a metabolic inhibitor in 1960 [24], have shown prom-
ise in the inhibition of cancer growth, although toxicity to
normal cells has been a limitation. It is worthwhile to ask
whether less toxic metabolic regulation of cancer cells is
possible in light of current thinking about cancer evolu-
tion, development and progression [25,20]. We have pre-
viously outlined a general hypothesis bearing on this [6]
and proposed, along with others [26] that human evolu-
tionary adaptations to starvation render normal cells tol-
Lack of non-specific protein inhibition Figure 2
Lack of non-specific protein inhibition. There is no sig-
nificant correlation between expression of cellular protein 
and the % change in ATP due to supplemental acetoacetate 
in the medium. r2 = 0.08 (p > 0.2) Data are from Table 1.
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(A): The effect of adding acetoacetate to glucose medium on ATP concentration and cell growth Figure 3
(A): The effect of adding acetoacetate to glucose medium on ATP concentration and cell growth. ATP and cell 
growth are both expressed as a percent of the respective values obtained at 96 h in 10 mM glucose (only) medium. M64 and 
M65 represent MCH 064 and MCH 065 cell lines, respectively. (B) The relation of cell growth to ATP concentration. Normal 
fibroblast controls RFP3, MCH 064 and 065 (in top right oval) demonstrate neither growth inhibition nor reduced ATP. All 
other data points represent seven cancer cell lines of Table 1 with parallel reduction in ATP and cell growth as also see in 3A. 
Regression equation plots growth (g) vs. ATP concentration (a) in blue in lower right of figure (p < 0.01). Data are from Table 
1.
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erant of flexible nutrient sources, including ketone bodies
and fatty acids.
On the other hand the initiation of a primary event trans-
forming a normal cell into a pre-malignant phenotype is
followed by a long period of subsequent adaptive cellular
response to a local hypoxic, nutrient-deprived microenvi-
ronment. During this interval of abnormal cellular growth
multiple adaptations eventually result in the cancer phe-
notype[27]. A typical response to the hypoxic environ-
ment, for example, is expression of insulin-independent
GLUT1's [25,28] triggered by HIF 1α [29] insuring maxi-
mum glucose uptake for glycolytic ATP generation. Solid
cancers require at least 30 to 35 generational doublings
before they attain a clinically detectable size of 1–2 cm
diameter (assuming average mammalian cell diameter of
10 microns) [30] over durations of 3 to 15 years. The
abundance and low cost of grain characteristic of efficient
modern agriculture has made sustained ketosis an unfa-
miliar internal metabolic environment for many people
living in developed countries [6]. It follows that in large
cohorts of individuals, sustained ketosis is not a familiar
microenvironment for newly evolving abnormal cells, on
the path to malignancy. Nevertheless, our normal tissues
remain adapted to these microenvironments as shown by
the absence of toxicity in experimental fasting of morbidly
obese individuals in the 1960's[31]. In human cancers in
the developed world, and in the absence of sustained
ketosis as a selective pressure over durations of 30 or more
doubling times, a diversity of evolutionary responses
should then be expected including accidental vulnerabili-
ties and survival adaptations. One response that would
correspond to an accidental vulnerability to ketosis would
be over-expression of UCP2 with intact TCA enzymes.
Conclusion
We have shown that acetoacetate added to glucose
medium causes variable but parallel reductions of ATP
concentration and cell growth in seven human cancer cell
lines. The effect lies along a continuum with control
fibroblasts at one extreme in which neither cell growth is
inhibited nor is ATP concentration reduced. The effect is
Cell growth vs. UCP2 expression in fibroblast controls vs. cancer lines Figure 4
Cell growth vs. UCP2 expression in fibroblast controls vs. cancer lines. Purple series represents UCP2 in cells grown 
in glucose medium; blue series represents cell lines grown in glucose plus acetoacetate. Cancer lines over-express UCP2 vs. 
control fibroblasts when grown in either medium. Asterisks reflect significant differences (p < 0.05) in UCP2 values for cells 
grown in G or G+AcA growth medium when compared to corresponding results from all fibroblast lines. Data are from Table 
1.
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consistent with an "inefficient" Randle cycle due to over-
expression of uncoupling protein 2, seen only in the can-
cer lines, and is plausible in light of current models of a
transformed cell's adaptive microscopic development and
progression toward the cancer phenotype. More work
must be done to prove metabolic inhibition by this mech-
anism. If proven, the results speak to the hypothesized
potential for ketogenic diets as non-toxic therapeutic strat-
egies, as adjuvants to standard therapies, and to multimo-
dality therapies to improve the control of malignant
disease.
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